ISSN:
1432-1041
Keywords:
PDX chloride
;
cholesterol
;
clofibrate
;
hyperlipoproteinaemia type II
;
bile acid sequestrant
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary Eleven patients with hyperlipoproteinaemia type II A, who were relatively resistant to hypolipidaemic drugs, were treated for four to six months with an anion exchange resin, Secholex® (PDX chloride), 15 g per day. The mean monthly plasma cholesterol level decreased by 10–18% (p〈0.01 andp〈0.001 respectively) from its pre-treatment value of 431±50 mg/100 ml (mean ±95% confidence limits). The reduction of plasma cholesterol was due mainly to a decrease in low density lipoproteins (LDL) of 50 mg/100 ml (p〈0.01). Very low density lipoproteins (VLDL) were moderately (p〈0.05) reduced and high density lipoproteins (HDL) remained unchanged. The mean pretreatment plasma triglyceride level (110±30 mg/100 ml) did not alter significantly. Nine of the patients had previously received clofibrate and in them Secholex reduced plasma cholesterol by 17% and clofibrate by 6%. Excluding one patient on clofibrate who had an unexpected increase in plasma cholesterol, there was little difference between the efficacy of clofibrate and Secholex. After four months two patients withdrew from the trial because of constipation. There was slight transient increase in mean serum alkaline phosphatase and a decrease in serum uric acid during treatment with Secholex.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00614393
Permalink
